Randomised clinical trial: the analgesic properties of dietary supplementation with palmitoylethanolamide and polydatin in irritable bowel syndrome
Randomised controlled trialHumansWith polydatin
This study tested palmitoylethanolamide together with polydatin. Its results cannot be assigned to palmitoylethanolamide alone. More combination studies.
- Design
- Randomised controlled trial
- Subjects
- 54 patients with irritable bowel syndrome and 12 healthy controls, at five European centres
- Dose used in the study
- 200 mg of palmitoylethanolamide with 20 mg of polydatin, twice a day
- Duration
- 12 weeks
- What was measured
- Mast cell counts and other biological markers in gut biopsies, and symptoms
What the authors reported
At the start of the study, IBS patients had higher mucosal mast cell counts than healthy controls (3.2% vs 5.3%, P = 0.013), lower levels of the related fatty acid oleoylethanolamide (12.7 vs 45.8 pmol/mg, P = 0.002), and higher expression of the CB2 cannabinoid receptor (0.7 vs 1.0, P = 0.012). The treatment did not significantly change the biological profile of the gut, including the mast cell count, which was the target it was chosen for. Compared with placebo, it improved the severity of abdominal pain (P < 0.05).
Limits of this study
The authors call it a pilot study. The biological outcome showed no change, and the authors state that the mechanism behind the pain result is unexplained. The entry was checked against the abstract only. Crossref lists the funder as CM&D Pharma, under licence of Epitech Group, which makes the product.
Source
PubMed 28164346 · doi:10.1111/apt.13958
Entry checked against the abstract on PubMed on 2026-10-19. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.